No spam - just the good stuff

Subscribe to our newsletter

News

Development

Drusolv targets macular degeneration with statin therapy

It’s time to sit up and take notice of mitochondria

Life Biosciences in-licenses IP from new studies

New studies in Nature "open a new frontier in biotechnology and medicine," says Life Biosciences CEO Mehmood Khan.

New Buck Institute study is treasure trove for longevity research

“Adjust the immune system… de-age the brain”

AI to quantify senescent cell counts

Senolytic start-up gears up for clinical trials

Gerostate Alpha: “Our phenotype is lifespan”

CohBar announces preclinical collaboration with NIAID

“The major modulators of aging remain to be discovered”

New Longevity supplement targets cognitive decline

Supplementing your Longevity knowledge

Senescence and the return of established splicing tech

Juvenescence (1): from strength to strength in R&D and investment firepower

A year in Longevity: progress perspectives

A year in Longevity: different perspectives

A year in Longevity: founders’ perspectives

A year in Longevity: science perspectives

VC and drug developer scale-up their incubator model

Longevity biomarker firm to align CROs, pharma and consumers

NAD boosting to reverse senescence and inflammaging

Sigilon IPO raises $145m to address chronic diseases

Deep Longevity reveals highly-accurate aging clock

BioAge CEO: “It’s all about the data.”

Silicon Valley is waking up to Longevity and senolytics

BioAge lands $90 million; gears up for clinical trials in 2021

Viral vector start-up aims to tackle gene therapy Longevity bottleneck

Biotech Elevian announces $15m equity financing

Targeting inflammaging: the hidden “inflammapath” inside us

AgeX Therapeutics reports Q3 financial results

Let’s initiate trials of potential geroprotective therapies

AgelessRx and funding an IRB-approved rapamycin trial

Find us here ...

Subscribe to our newsletter

© Copyright 2023 FIRST LONGEVITY Limited. All rights reserved. FIRST LONGEVITY

First Longevity Ltd is an appointed representative of Prospect Capital Ltd which is authorised and regulated by the Financial Conduct Authority.
The information included in this website is for informational purposes only: its purpose is to promote a broad consumer understanding and knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.